Class-Action Status for Rezulin Cases Rejected
From Times Wire Reports
Pfizer Inc. won’t have to face a nationwide class-action suit over its Rezulin diabetes drug that’s been linked to liver problems, a federal judge ruled.
U.S. District Judge Lewis A. Kaplan rejected a bid by plaintiffs to combine claims from more than 2 million former Rezulin users into a single case in federal court in New York. Kaplan said consumers’ problems with the drug were too individualized to warrant treatment as a class.
The decision comes after a California judge’s ruling this year that Pfizer and its Warner-Lambert Co. unit weren’t subject to a class-action suit claiming the drug’s advertising misled consumers about health risks.
